BEIJING, May 4 /PRNewswire/ -- Accelovance, a Rockville, Maryland based
company with a wholly foreign owned enterprise (WFOE) in China held its
Accelovance (China) office Grand Opening ribbon cutting ceremony as part of
Maryland Beijing Reception last Thursday. This is a key step in the company's
strategy to bring a global solution to meeting trial timelines. The Beijing
office will serve as the base of operations for clinical sites scheduled to be
functioning within 9 months. Sites in China will provide Accelovance's
clients with a strategic alternative to their clinical trial needs and will
add to the existing 12-site network in the United States.
In attendance were 150 guests including representatives from China's
Ministry of Foreign Affairs, Ministry of Health, State Food & Drug
Administration, Ministry of Science & Technology, Beijing municipal
government, as well as representatives from clinical research centers, global
pharmaceutical companies and Chinese pharmaceutical industry. This event
brought further attention to the continued promotion of the business
collaboration between the State of Maryland and China.
"We are very excited to be starting our China operations and to be part of
the growing collaboration between Maryland and China," commented Accelovance
President and CEO, Stephen J. Trevisan. "China brings tremendous value to
clinical trial performance. There is a wealth of highly qualified and
talented researchers, patients can be enrolled rapidly, and trials can be
conducted in a very cost effective manner."
Dr. Ken Ren, President of Accelovance China agreed, "We are closer to
fulfilling our vision of becoming a global trial management organization.
With the growing compliance with international GCP standards, the large number
of well-educated and experienced investigators, and huge treatment-naive
patient population, China represents one the most attractive areas for
conducting global clinical trials for new drug development."
Headquartered in Rockville, Maryland, Accelovance is a privately held
company that has 12 clinical sites in the United States. In China, the
Company will operate through its wholly-owned enterprise in Beijing and
establish clinical site networks in the country. Accelovance provides Phase
II-IV clinical trial services across a breadth of therapeutic areas that
include investigator selection, patient recruitment and study management
services for pharmaceutical, contract research organization (CRO), and
biotechnology industries. The company is focused on optimizing the quality
and productivity of multiple clinical sites, through strong central management
and targeted pro-active patient recruitment. Delivering high quality and
timely clinical trial support services, Accelovance is committed to
understanding and meeting its clients needs to ensure their success.
For more information, visit the company's website at
CONTACT: Media: Garrett D. Smith at 301.222.2212